On November 12, 2026, Minerva Neurosciences, Inc. filed a Current Report on Form 8-K disclosing details regarding a key opinion leader (KOL) event held on that same date. The event focused on roluperidone, the company’s product candidate intended for the treatment of negative symptoms in patients diagnosed with schizophrenia.
Frank Sasinowski, the company’s regulatory counsel, participated in the discussion. He provided personal views concerning the potential regulatory outcome should the company receive positive results from the initial 12-week, placebo-controlled portion of the ongoing C19 Phase 3 clinical trial, known as Phase A. The company clarified that Mr. Sasinowski’s expressions of confidence regarding potential approval reflected his personal opinions and predictions and should not be understood as assurances regarding any future action or decision by the U.S. Food and Drug Administration (FDA).
The filing indicates that any decision by the company to resubmit its New Drug Application (NDA) for roluperidone will depend on the results of the C19 trial, the complete data package, and further assessment. Positive results from Phase A would not, by themselves, assure approval of a resubmitted NDA. The FDA has not committed to approval of roluperidone, and the acceptability of any resubmission and the ultimate regulatory outcome remain subject to the FDA’s review of the complete submission.
To address the nature of the statements made during the KOL Event, the company furnished a revised transcript as Exhibit 99.1. This revised transcript removes the question-and-answer session, during which statements concerning approval predictions, safety, and professional relationships were made. The company emphasized that investors should not rely on the statements that have been removed and that the revised transcript supersedes any previously published transcript of the event.
In addition to the revised transcript, the company filed an updated investor presentation as Exhibit 99.2, which may be used in conversations with investors and analysts. The company remains committed to completing the relapse comparison portion of the C19 trial, known as Phase B, and maintains ongoing discussions with the FDA.